The contribution of the ETS2 transcription factor to the transformed state in prostate cancer cells has been assessed. Northern blot analysis easily detects ETS2 in DU145 and PC3, high grade human prostate cell lines, but ETS2 is not present in lower grade LNCaP cells. Stable transfection of PC3 and DU145 prostate cell lines with an antisense ETS2 vector or with a dominant negative ETS2 mutant signi®cantly reduced the ability of DU145 and PC3 cells to form large colonies in soft agar. Thus, the presence of ETS2 is positively correlated with a more transformed phenotype and blockage of ETS2 function can reduce transformed properties of prostate cancer cells.
Introduction
In United States, it is estimated that during the last 15 years of the 20th century, there will be a 37% increase in prostate cancer deaths per year and a 90% increase in the incidence of disease diagnosed (Carter and Coey, 1990) . In males, cancer of the prostate now exceeds lung cancer as the most frequently occurring type of cancer and it is second only to lung cancer in the cause of death due to malignancy (Landis et al., 1998; Parker et al., 1997) . Indeed, for 1998, an estimate of 39 200 deaths and 184 500 new presentations of prostate cancer has been predicted (Landis et al., 1998; Parker et al., 1997) . Although the steady increase in the age adjusted incidence and mortality of this disease is startling, when the increment in the aging population of the US is considered, the dilemma of prostate cancer becomes even more alarming (Bostwick et al., 1992; Carter and Coey, 1990) . Autopsy studies have revealed that as much as 30% of men over the age of 50, and 73% of men over the age of 75 have identi®ed prostate carcinomas without having evidenced clinical symptoms . Although the predominant presentation of prostate malignancy is as a well dierentiated, slowly growing tumor in elderly males, at present there is no way to determine whether a tumor will become aggressive and metastasize or remain indolent with little potential for metastasis. Since typical treatment of late stage prostatic malignancy entails chemical or physical castration, and early stage prostatectomy often causes impotency, these procedures often require decisions that greatly in¯uence quality of life. What is needed, aside from the ability to merely detect the presence of malignancy, are clinical markers that distinguish those prostatic carcinomas which are potentially aggressive from those that are unlikely to cause advanced prostate cancer (Mohler et al., 1992) . Thus, knowledge of genetic expression at the molecular level in this type of tumor tissue could likely lead to the discovery of genes that might be activated, dysregulated or otherwise essential to the progression of prostatic malignancy and its subsequent metastasis.
Alterations in proper control of cellular pathways that regulate cell growth and dierentiation can result in cellular transformation leading to cancer. Dysregulation of transcription factor protooncogene expression results in the development of several neoplasias (Cleary, 1991) . Investigations in our laboratory lead to the discovery of ETS2, a member of the ETS gene family of sequence-speci®c transcription factors (Watson et al., 1988 (Watson et al., , 1990 . All Ets proteins contain a conserved DNA binding domain (Ets domain) of about 85 amino acids that recognizes purine rich sequences containing a -GGAA/T-core (Bassuk and Leiden, 1997; Papas et al., 1997; Watson et al., 1990) . Ets proteins have important roles in the transcriptional control of genes important for development, angiogenesis, cell cycle control and cell proliferation. The involvement of Ets genes in cancer was ®rst demonstrated by the presence of Ets sequence in the oncogenic virus, E26 and their importance in human carcinogenesis has been shown by the observation that members of the Ets family are located at the translocation breakpoints of leukemias and solid tumors, forming chimeric proteins with transforming properties (Bassuk and Leiden, 1997; Papas et al., 1997; Watson et al., 1990) .
ETS2 is involved in the regulation of cell division, since it has been shown to be a regulator of cdc-2 (Wen et al, 1995) and cyclin D1 (Albanese et al., 1995) . Furthermore, increased ETS2 expression is observed during liver regeneration following partial hepatectomy (Bhat et al., 1987) and after activation of T-cells (Bhat et al., 1990) and macrophages (Boulukos et al., 1990) . ETS2 has an important role in signaling response through the CSF-1 (Langer et al., 1992) and Neu/ ErbB-2 (Galang et al., 1994) cell surface receptors. Inappropriate ETS2 expression may lead to cellular transformation: Constitutive ETS2 expression transforms NIH3T3 cells, making them tumorigenic (Seth et al., 1989) . Recently, ETS2 has been shown to be expressed at elevated levels in cervical (Simpson et al., 1997) and prostate cancer (Liu et al, 1997) . However, the role of ETS genes in human prostate cancer remains to be directly explored.
In the present study, we examined the role of ETS2 in prostate cancer, using cell lines as models for human prostate cancer. LNCaP is an androgen-sensitive, welldierentiated line and has a low level of tumor aggressiveness in vitro and in mice. In contrast, DU145 and PC3 are not responsive to androgens and are poorly dierentiated and represent a more aggressive form of tumor. We examined whether modulation of ETS2 expression in prostate cancer cells can alter their ability to form colonies in soft agar, a property of transformed cells. Furthermore, we tested whether inhibition of ETS2 function by expression of an ETS2 dominant negative mutant aects anchorage independent growth of prostate cancer cells. The ®ndings from our studies support the hypothesis that ETS2 controls the expression of genes required for the carcinogenic transformation of prostate cells.
Results

Expression of ETS2 mRNA in human prostate cell lines
To initiate our analysis of the role of ETS2 in prostatic cancer, we examined the expression of ETS2 in three commonly used human cell lines, derived from prostate cancer. We prepared RNA from three cell lines (LNCaP, DU145 and PC3). Northern analysis demonstrates that the ETS2 mRNA products (4.7, 3.2 and 2.8 kb) are expressed at signi®cant levels in the DU145 and PC3 cell lines, while they are not present at detectable levels in LNCaP (Figure 1 ). This observation is consistent with the hypothesis that ETS2 expression is associated with cell lines representing a more aggressive phenotype.
To assess whether ETS2 expression is related to the transformed state of prostate cancer cells, we performed an mRNA`knockdown' experiment by transfection of DU145 and PC3 prostatic cancer cells with a plasmid that constitutively expresses an antisense ETS2 RNA. Following selection in G418, individual clones were screened by Northern blot hybridization for the presence of the exogenous ETS2 mRNA. DU145 and PC3 antisense ETS2 clones that demonstrated a decrease in the expression of the endogenous ETS2 4.7 kb mRNA species were chosen for further analysis (Figure 2 ; Note: The antisense RNA co-migrates with the smaller 3.2 kb and 2.8 kb ETS2 mRNAs).
ETS2 expression correlates with the transformed phenotype of DU145 and PC3 prostate cancer cells Two clones expressing the antisense RNA and no longer expressing the endogenous ETS2 message (Figure 2 ), along with each parental cell line, were tested for anchorage independent growth, a cellular phenotype that is correlated with in vivo tumorigenicity. The ability of DU145 and PC3 to form large colonies in soft agar was signi®cantly decreased in the antisense transfectants ( Figure 3 ). After 3 to 4 weeks in soft agar, the transfectants have a reduced ability to form large colonies. The quantitative data on the colony numbers shows that the reduction of large (4280 mm) colonies is signi®cantly greater than for small colonies (140 ± 280 mm). These changes in colony formation in soft agar do not appear to be related to growth rate, since the transfected cells and parental cells have similar growth rates when grown on plastic culture dishes (data not shown). These results support the hypothesis that the presence of ETS2 can be positively correlated with a more transformed phenotype (anchorage independent growth).
Reversal of transformed phenotype of prostate cancer cells by blockage of ETS function
Expression of the DNA binding domain of Ets transcription factors in the absence of their transactivation domain has been shown to suppress the transcription of Ets target genes (Langer et al., 1992 ; Reduction of endogenous ETS2 expression in stable antisense transfectants of PC3 and DU145 is observed Wasylyk et al., 1994) . A DNA segment encoding the C-terminal 137 amino acids of the human ETS2 protein, including the DNA binding domain and sequences required for nuclear localization, was cloned into a modi®ed pSG5 eukaryotic expression vector under the control of the SV40 promoter. The plasmid, pDN-ETS2, was transfected into DU145 cells and independent stable cell lines were obtained. Stable transfectants were analysed for the presence of the exogenous 1.0 kb ETS2 mRNA by Northern blot hybridization (Figure 4a ). DU145 transfectants expressing the DN-ETS2 transcript were expanded and compared with the parental cell line for the presence of the truncated ETS2 protein. Radioimmunoprecipitation analyses were performed using two dierent ETS antibodies recognizing the DNA binding carboxy terminal domain. Both antibodies (Figure 4b , pan ets (a) and C20 (b)] precipitated a protein of approximately 16 kDa from the two transfectants, but not from the parental cells. This size is consistent with the predicted size of 15 960 kDa. These two independent clones were compared with the parental cell line for anchorage-independent growth. Compared with the DU145 parental cell line, the DN-ETS2 transfectants do not grow well in soft agar ( Figure 5) . Thus, inhibiting ETS2 function reverses the transformed phenotype of prostate cancer cell lines.
Discussion
Prostate cancer has been dicult to manage clinically because it yields few clues that portend aggressive behavior. Cancer is the result of the an accumulation of multiple genetic changes, resulting in either the loss of expression of tumor suppressor genes or overexpression of oncogenes. While a number of important (Isaacs, 1997) , it has been dicult to correlate changes in these genes to the onset of an aggressive clinical course. In fact, a large number of genetic defects accumulate at a greater rate than can be explained by ordinary mutation rates. Given this accelerated rate of genetic alterations, we propose that the stochastic nature of prostate tumor progression could be due in part to the dysregulation of transcription factor expression. Alterations in a transcription factor are likely to aect many other genes, some of which ultimately lead to the outgrowth of cells whose normal controls on growth and invasiveness have been compromised.
The goal of this study was to assess the contribution of one member of the ETS gene family, ETS2, in prostate cancer. Transfection provides a model system in which we can manipulate ETS2 expression in prostate cancer cells to determine its contribution to the transformed phenotype. Two approaches to block ETS2 function in DU145 and PC3 human prostate cell lines that express ETS2 have been developed. We have generated clonal cell lines that express an antisense construct and consequently no longer express the endogenous ETS2 transcripts. In addition, we have inhibited ETS2 function as a transcription factor by creating prostate cell clones expressing a transdominant negative mutant that is likely to compete with endogenous ETS2 protein for Ets binding sites. Cell lines that no longer have functional ETS2 have a much reduced ability to grow in an anchorage independent manner compared to the parental cell lines. The results presented support the model that ETS2 function(s) are necessary for the maintenance of the transformed phenotype of prostate cancer cells and that dysregulation of the ETS2 gene control contributes to aggressive prostate cancer. Furthermore, ETS2 may play a role in controlling genes that are misexpressed in aggressive cancer and our cell lines provide a system will allow identi®cation of Ets target genes that are associated with cancer progression. Interestingly, DU145 and PC3 (ETS2 expressing) prostate cancer cell lines are invasive, while LNCaP (not expressing ETS2) are not, as measured by migration through Matrigel coated membranes (Wasilenko et al., 1996) . Elevated expression of ETS2 in invasive cells is consistent with Ets function in the regulation of stromelysin (Gutman and Wasylyk, 1990 ) and collagenase (Wasylyk et al., 1991) , enzymes that degrade extracellular matrix. Plasminogen activator urokinase (u-PA), an Ets target (Nerlov et al., 1991) is necessary for in vitro invasiveness and metastasis of PC3 cells (Crowley et al., 1993) . Other Ets target genes have been found to be upregulated in prostate cancer and function to promote cell proliferation, motility and angiogenesis, properties that play critical roles in carcinogenic progression. For example, c-met, the receptor for hepatocyte growth factor/scatter factor, is regulated by Ets (Gambarotta et al., 1996) and the presence of met protein has been correlated with higher grade adenocarcinomas (Pisters et al., 1995) . Mitogenic signaling through the ErbB/neu receptor is mediated through Ets (Galang et al., 1996; Langer et al., 1992) and elevated neu expression is associated with metastatic conversion of prostate cancer (Zhau et al., 1992 (Zhau et al., , 1996 . In addition to regulating genes overexpressed in prostate cancer cells, Ets has recently been shown to regulate maspin, a tumor suppressing protease inhibitor that is expressed in normal prostate epithelial cells and down-regulated in prostate cancer cell lines (Zhang et al., 1997) . Lower expression of maspin in LNCaP cells was due in part to the loss of Ets-mediated transcriptional activation (Zhang et al., 1997) . Collectively, these observations demonstrate the importance of Ets target genes in prostate cancer.
Due to the similarity of Ets binding sites, it is quite likely that the DN-ETS2 mutant can inhibit the transcriptional activity of other ETS family members. Thus, in addition to inhibiting ETS2 transcriptional targets, it is expected that the DN-ETS2 mutant would also block the transcriptional activity of other ETS family members that are expressed in prostatic cancer cell lines (e.g., ETS1, unpublished observations). Thus, interference of Ets function may provide a novel therapeutic approach for cancers that overexpress Ets family genes.
Materials and methods
Cell lines, tissue culture and DNA transfection
The human prostatic carcinoma cell lines LNCaP, DU145 and PC3 were obtained from American Type Culture Collection (Rockville, MD and were propagated at 378C, with 5% CO 2 in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). The LNCaP cell line originated from prostatic tumor cells metastasized to a supraclavicular lymph node. It has been found to possess chromosomal deletions at 7q22, 10q24 and 16q22 and contains a wild type p53 gene. It has a well-dierentiated phenotype, is androgen sensitive and PSA and prostatic acid phosphatase positive. Based upon these properties, LNCaP has been used as a model for well-dierentiated prostate cancer. LNCaP is weakly tumorigenic and not metastatic after Figure 5 Mutant ETS2 (DN-ETS2) inhibits anchorage-independent growth. Soft agar colony assays for parental DU145 and DN-ETS2 transfectants (DU DN21, DU DN30) were quantitated after 3 weeks subcutaneous injection into nude mice. The DU145 line was derived from a brain metastasis. It has an aneuploid number of chromosomes (between 61 and 65), and has a deletion of the RB gene and a mutation in p53. It is androgen insensitive, PSA negative and is tumorigenic. The PC3 line was derived from a bone metastasis (grade IV adenocarcinoma), and is aneuploid, with a mean number of chromosomes ranging from 55 ± 58. The PC3 cell line is mutated in p53 and is tumorigenic. The properties of DU145 and PC3 suggest that they represent poorly dierentiated, aggressive prostate cancer. Parental cell lines and transfectants were tested for mycoplasma contamination and were not infected.
DU145 and PC3 cells were transfected using LipofectAmine (10 ml/35 mm well, Life Technologies Inc., Bethesda, MD). Stable DU145 and PC3 transfectants were expanded in the presence of 300 mg/ml G418.
Soft agar growth assays were performed in six-well plates (35 mm wells). Cells (20 000) were plated in 0.4% agar (Sigma) in RPMI 1640 supplemented with 10% FBS. An underlayer of 0.6% agar was used to prevent attachment of cells. Triplicate assays initiated with 20 000 cells were fed weekly by agar overlay and scored after 3 or 4 weeks, as indicated in the ®gure legends. The soft agar assays were performed twice, independently.
Expression vectors
ETS2 cDNA (SstII to HindIII fragment from pK3A (Watson et al., 1988) was subcloned in antisense orientation into the eukaryotic expression vector, pSGneoKS (modi®cations of pSG5 (Stratagene, La Jolla, CA) containing a neomycin/G418-resistance cassette and the multiple cloning site from pBluescript II KS vector). The pK3A vector, primers and Pfu polymerase were used to PCR amplify a portion of the human ETS2 cDNA encoding the DNA binding domain (C-terminal amino acids, 333-469). The 5' primer (GAGAACTAGTACCAC-CATGGATTACATCCAAGAGAGGA) contains the recognition sequence for SpeI and a Kozak consensus start sequence in frame with aspartic acid residue 333 of the ETS2 cDNA to allow for ecient protein translation. The 3' primer (GAGACTCGAGGCGACCTCAGTCCTCCG-TGTC) contains the recognition sequence for XhoI and the translation termination codon from the ETS2 gene. The resultant PCR product was digested with SpeI and XhoI and cloned in the sense orientation between the SpeI and XhoI sites of the pSGneoSK to generate the pDN-ETS2
vector. Orientation and sequence of all constructs were veri®ed by sequence analysis (ABI 373).
RNA extraction and analysis
RNA from cultured cells was puri®ed using RNAStat (TelTest, Inc., Friendswood, TX). Total RNA was fractionated on 1.2% agarose gels containing 0.66 M formaldehyde (2.2 M in the sample) by the method of Lehrach et al. (1977) . Gels were transferred to Duralon ®lters (Stratagene) in 0.1 M sodium phosphate (pH 6.8), UV crosslinked, and hybridized in Quik-Hyb (Stratagene) using 32 Plabeled human ETS2 probe (Watson et al., 1988) .
Cell labeling and immunoprecipitation
Prostate cancer parental cells and transfectants were grown in 100 mm dishes to 70 ± 80% con¯uence. After methionine-starved for 30 min, cells were labeled in methioninefree RPMI 1640 with 35 -S-methionine (200 mCi, 41000 mCi/mmole, Amersham) for 60 min. Labeled cells were harvested, washed with PBS and lysed in RIPA buer containing protease inhibitors (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% SDS, 1.0% Triton X-100, 1 mM EDTA, 0.1 mM EGTA, 0.5 mM PMSF, 0.1 mM TPCK, 0.01 mM TLCK, 2 mM pepstatin A, 0.6 mM leupeptin, 1% aprotinin). Five 610 7 c.p.m. (trichloroacetic acid precipitated) of the cleared lysates were incubated overnight at 48C with 1 mg of either antibody [Ets2, C20, Santa Cruz, CA or pan ets (Bhat and Papas, 1992) ]. Pan ets immunocomplexes were incubated with 2 mg rabbit antimouse Fc antibody (Pierce, IL) for 1 h. 5 mg Protein A Sepharose CL-4B (Pharmacia, NJ) was added and incubated for an additional hour at 48C. The immunoprecipitates were washed 6 times in cold SDS-free RIPA and boiled in protein loading buer (16: 5% glycerol, 5% bmercaptoethanol, 3% SDS, 0.1% Bromphenol blue). The supernatant was collected after centrifugation at 12 000 g for 5 min and resolved by SDS ± PAGE, and analysed bȳ uorography.
